Reports FY23 revenue $1.71M vs. $766,277 for FY22. “This year has been pivotal for us, with our revenue more than doubling, it’s a clear indicator of our market strength and customer trust,” stated Elevai Labs CEO, Jordan Plews. “We are proud to have increased our operating, production and supply chain efficiency as evidenced in the improvement of our gross margin and are excited to further advancements at the interface between aesthetics and biotechnology. This marks just the beginning of our ambitious vision for the future.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
- Elevai Labs announces the launch of its online E-commerce portal
- Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
- ELEVAI Labs Inc.: Stock Price Woes and Board Reshuffle
